Lateral Diagnostics

Breakthrough handheld diagnostics devices providing lab-like...


Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

Lateral Diagnostics: Fast Facts

With proprietary quantitative lateral flow technology, Lateral Diagnostics is developing breakthrough diagnostics devices that deliver fast, affordable, lab-like results.

Our flagship device enables point-of-care and at-home testing for diabetics to actively monitor and manage their disease.

Increasingly Prevalent Disease 

In 2019, 37.3 million Americans, or 11.3% of the population, had diabetes. 1.4 million Americans are diagnosed with diabetes every year. Currently, it is estimated that over 100 million Americans aged 18 and older have prediabetes. Convenient professional and home access to testing technology is needed to help these patients diagnose and manage their condition.

Introducing Lateral Diagnostics.

Accessible Testing

Lateral Diagnostics develops point-of-care and at-home diagnostics tests that deliver lab-like results faster and at less cost than traditional testing methods.

As one of the first accurate handheld diabetes management (HbA1c) devices in development, our device will allow physicians to quickly test patients at the point of care or allow patients to test themselves at home.

With more timely and convenient access to testing, we equip adults with pre-diabetes and diabetes with the resources to manage their disease better throughout the year.

Key Features & 
How It Works

A product of 15 years of dedicated research, our handheld device is an orchestra of innovative chemistry, optics and software that deliver lab-like performance in small form factor.

Our flagship product, a wet chemistry HbA1c device for diabetes testing, affords lower production costs and a quicker time to market. 

Development Milestones & Partnerships

Lateral Diagnostics has demonstrated clinical viability with our prototype device.

We are pursuing several patents for design, materials and methods.

  • Patents for first-gen HbA1c reader and cartridges.
     o Design, material and methods patents for other assays in planning stage.
  • Patents for second-gen HbA1c reader and cartridges.
  • Design, material and methods patents for second-gen HbA1c system. 

We have key relationships with all major and minor distributors. Our leading contract sales force is interested in adding our product to their portfolio.

Meet Our Team

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.

Request Access


No updates yet.


No backers yet.

Quick Signup TBD

You must have an account to do this!

the platform

Copyright © 2019 All rights reserved.

Fundable is a software as a service funding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.